# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan reiterates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and maintains $35 pr...
HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $90 price ...
B of A Securities analyst Tazeen Ahmad maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target fr...
HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $90 price ...
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineer...
HC Wainwright & Co. analyst Andrew Fein maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and lowers the price targ...
Citigroup analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $26 to...
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $...